UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

FDA lifts hold on clinical trial testing gene-editing therapy for ATTR-CM

Source
Amyloidosis News Today

The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate, known as nex-z for short, in adults with transthyretin amyloid cardiomyopathy (ATTR-CM).

The regulatory agency had placed the clinical hold on the Phase 3 MAGNITUDE trial (NCT06128629) — which had then already enrolled more than 600 patients — late last year due to safety concerns. Specifically, an older man with ATTR-CM developed life-threatening liver damage and eventually died after receiving the therapy in the trial.